Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC: World’s leading Event Organizer

Conference Series Conferences gaining more Readers and Visitors

Conference Series Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Renowned Speakers

Abdulaziz Aldawood

Abdulaziz Aldawood

Deputy Chairman
King Saud Bin Abdulaziz University ,Saudi Arabia

Nadia Ameen

Nadia Ameen

Principal Investigator
Yale University School of Medicine ,USA

Weida Tong

Weida Tong

Director
National Center for Toxicological Research ,USA

Joseph N Dung

Joseph N Dung

Head of Neglected Tropical Diseases ,Switzerland

Alice Abdel Aleem

Alice Abdel Aleem

Assistant Prof. Neurology
Weill Cornell Medical College ,Qatar

Marc Dooms

Marc Dooms

Production Manager
Center for Clinical Pharmacology ,Belgium

Diego Alvarez

Diego Alvarez

Anahuac University North Campus ,Mexico

Jong Wook Chang

Jong Wook Chang

Samsung Medical Center ,South Korea

Rare Diseases Congress 2017

About Conference

Conference series LLC to attend welcomes every intrigued possibility to attend the 2nd World Congress on Rare Diseases and Orphan Drugs which will be held in June 29-30, 2017 in London, UK. The theme of this current year conference is “Novel Approaches to explore the emerging insights in the Rare Diseases Research”. Rare diseases, likewise alluded as orphan diseases, are portrayed by their low event with dominant part of them are serious chronically and life undermining. Rare Diseases Congress-2017 conference will serve as a method for imparting a more viable discourse on how the research world can address an overlooked rare disease. This intriguing occasion is sorted out to give an interesting stage to instructors, the scholarly world, new scientists from multiple disciplines, and learners from top universities to disseminate and discuss the upcoming innovations, potential outcomes in treatment of uncommon illnesses.

Target Audience:

· Rare Disease Associations and Societies

· Medical Colleges

· Pharmaceutical Companies and Industries

· Health care professionals

· Students, Scientists

· Researchers

· Training institutes

· Drug manufacturing companies

Why to attend?

World Congress on Rare Diseases is giving a worldwide stage to analysts that afford new insights into the concealed rare diseases. An expanding number of distinguished rare diseases makes it makes it important to complete propelled research here of irresistible sicknesses. World-eminent speakers, improvements, and the most up to date upgrades are particular components of this gathering and with individuals from around the globe concentrated on finding out about uncommon illnesses and its advances; this is your best chance to achieve the biggest collection of members, conduct presentations, disseminate data, meet with potential scientists, trade learning on late improvements and make an unmistakable imprint by invigorating development at this event.

Tracks

· Rare Disease and its Cause

· Pediatric Rare Diseases

· Rare Aging Disease

· Rare Disease in oncology

· Rare Ophthalmological Diseases

· Rare Metabolic Diseases

· Genetic Diseases and Disorders

· Neurological Diseases

· Rare Pulmonary Diseases

· Hematological Diseases

· Nursing and Rare Disease

· Therapies for Rare Diseases

· Potency of Orphan Drugs

·Strategies for Diagnosis &Treatment

· Legal Issues Related to Rare Diseases

· Current Research on Rare Diseases

Sessions/Tracks

Track 1: Rare Disease and its Cause

Rare diseases are a multiple heterogeneous group of diseases with a little in like manner aside from of their irregularity affecting with influencing the individuals. 80% of rare diseases have distinguished hereditary inceptions and others may have some ecological variables, there are wide and several which are yet to be examined. Some rare diseases are acquired while some influenced individuals go about as Diseases examined. Despite irregularity, they represent an important medical and health problem because of their occurrence. For multiple rare diseases have no treatment, but if it exists and if started on time as accessibly available to patients, there is a good prognosis for them to be able for normal life. The issues of patients reflected and influenced by rare diseases are identified with the absence of diagnosis and timely undergoing as well as their treatment or counteractive action.

Related Conferences

Annual Conference on Rare Diseases and Orphan Drugs, Oct 26-27, 2016 USA; 2nd International Conference on Flu, Oct 31- Nov 2, 2016 in San Francisco, USA;4th World Congress on Infection Prevention and Control, Nov 28-29, 2016 (9 Keynotes, 1 Special session, 2 Days,1 Event) Valencia, Spain; International congress on Infectious Diseases, May 11-12, 2017 Barcelona, Spain;5th International Congress on Bacteriology and Infectious Diseases, May 25-26, 2017 USA;4th International Conference on Chronic Obstructive Pulmonary Disease (COPD), May 29-31, 2017 Japan; International Conferences on Rare Diseases and Orphan Drugs Cape 19-22 Oct 2016, South Africa;19th International Conference on Infectious Diseases , Jan 26 - 27, 2017 Sydney Australia; Advances in Basic and Translational Research in Tropical Infectious Diseases ,Mar 12-17, 2017 Hotel Galvez Galveston, TX; Keystone Symposia: New developments in our basic understanding of tuberculosis, Jan 14-18, 2017 Canada; 35th UC Davis Annual infectious diseases conference Feb 03-04, 2017 USA

Related Societies:

Rare Diseases Europe; Rare Disorders Society; BPSU – Rare;   Canadian Society for Mucopolysaccharide and Related Diseases; Rare Diseases UK, Rare Diseases South Africa, Students 4 Rare Diseases, National Organization for Rare Disorders; American Association of Pharmaceutical Scientists

Track 2: Pediatric Rare Diseases

Rare Diseases associated with Pediatric Condition is an inherited, genetic condition. Patients have recurring fevers, which occurs almost daily with the disease development in Pediatric children. They also present with delayed development, skin rashes and unique and rare conditions in facial features such as thicker lips, swollen eyelids and eye balls. Children will develop swelling around the eye sockets, and also clubbing of fingers and toes and gradual enlargement of the liver and also growth of multiple cells. Over time there is a loss of muscle control and some wasting of brain tissue. The specific condition in which the heart muscles become diseased and the heart becomes enlarged and weak. Babies with the infantile form usually leading to death before their first birthday due to the rare condition in heart failure and respiratory weakness.

Related Conferences

4th International Conference on Sexually Transmitted Diseases, Jun 19-20, 2017 UK ;International Conference on Vector Borne Diseases ,June 29-30, 2017 Philadelphia, USA;3rd International Conference on Retroviruses and Novel Drugs ,July 27-28, 2017 Vancouver, Canada;3rd International Conference on Influenza ,Aug 21-22 2017 Birmingham, UK;3rd World Congress on Infectious Diseases ,Aug 21-23, 2017 California, San Francisco, USA; 24th Conference on retroviruses and opportunistic infections Feb 13-16, 2017 USA; Keystone Symposia-Malaria: From innovation to eradication, Feb 19-23, 2017 Uganda; Australasian society for infectious diseases annual scientific meeting, Mar 29-Apr 01, 2017; ICHA 2017: 19th International Conference on HIV and AIDS ,May 25-26, 2017 London, UK; STI & HIV World Congress ,July 9-12, 2017 Rio de Janeiro, Brazil

Related Societies:

American Pediatric Society; Society for Pediatric Research; ESPR European Society for Paediatric Research; The Latin American Society for Pediatric Research; Pediatric Academic Societies; Rare Diseases UK, Rare Diseases South Africa, Students 4 Rare Diseases, National Organization for Rare Disorders; American Association of Pharmaceutical Scientists

Track 3Rare Aging Disease

The regularity of rare diseases among adults individuals and elderly is not infrequent as the youngsters experiencing a specific unique disease and are under treatment may progress the same life long. Bringing focus on this zone of infections would be rapid and quicken the exploration and disease treatment and in this way would be effective in treating most extreme number of rare ailments. Studies have shown that 37.5% had ordinary lifespan, 25.7% potentially lethal during childbirth or before 5 years of age, 36.8% diminished lifespan.

Related Conferences

4th International Conference on Sexually Transmitted Diseases, Jun 19-20, 2017 UK ;International Conference on Vector Borne Diseases ,June 29-30, 2017 Philadelphia, USA;3rd International Conference on Retroviruses and Novel Drugs ,July 27-28, 2017 Vancouver, Canada;3rd International Conference on Influenza ,Aug 21-22 2017 Birmingham, UK;3rd World Congress on Infectious Diseases ,Aug 21-23, 2017 California, San Francisco, USA; 24th Conference on retroviruses and opportunistic infections Feb 13-16, 2017 USA; Keystone Symposia-Malaria: From innovation to eradication, Feb 19-23, 2017 Uganda; Australasian society for infectious diseases annual scientific meeting, Mar 29-Apr 01, 2017; ICHA 2017: 19th International Conference on HIV and AIDS ,May 25-26, 2017 London, UK; STI & HIV World Congress ,July 9-12, 2017 Rio de Janeiro, Brazil

Related Societies:

American Society on Aging; International Society on Aging and Disease; Aging and Society; Society for Pediatric Research; ESPR European Society for Paediatric Research; The Latin American Society for Pediatric Research; Vitreo Retina Society of IndiaGlaucoma Society of India; Uveitis Society of India Oculoplastics Association of India;  Strabismological Society of India

Track 4: Rare Diseases in Oncology

Rare Oncology disease has a mandate to accost the recent challenges presented by rare cancers and diseases as well cancers that may be predominant in medically unreasonable populations. CCR investigators, both at the laboratory bench and in the clinic, are actively involved in this research studies.  In many cases, the knowledge CCR’s investigators gain from studying and treating rare cancer diseases and related disorders provides them with insights into the mechanisms that underlie other more common malignant syndromes.  It is very worthy consideration for oncologists to keep updated of the latest advancements in oncology, as changes in management of cancer are shown quite common. All eligible patients in whom cancer progresses and for whom no general of care treatment strategies are available should be enrolled in a clinical trial.

Related Conferences

Annual Conference on Rare Diseases and Orphan Drugs, Oct 26-27, 2016 USA; 2nd International Conference on Flu, Oct 31- Nov 2, 2016 in San Francisco, USA;4th World Congress on Infection Prevention and Control, Nov 28-29, 2016 (9 Keynotes, 1 Special session, 2 Days,1 Event) Valencia, Spain; International congress on Infectious Diseases, May 11-12, 2017 Barcelona, Spain;5th International Congress on Bacteriology and Infectious Diseases, May 25-26, 2017 USA;4th International Conference on Chronic Obstructive Pulmonary Disease (COPD), May 29-31, 2017 Japan; International Conferences on Rare Diseases and Orphan Drugs Cape 19-22 Oct 2016, South Africa;19th International Conference on Infectious Diseases , Jan 26 - 27, 2017 Sydney Australia; Advances in Basic and Translational Research in Tropical Infectious Diseases ,Mar 12-17, 2017 Hotel Galvez Galveston, TX; Keystone Symposia: New developments in our basic understanding of tuberculosis, Jan 14-18, 2017 Canada; 35th UC Davis Annual infectious diseases conference Feb 03-04, 2017 USA

Related Societies:

American Society of Clinical Oncology; American Cancer Society; European society of Pediatric Hematology Oncology; Indian Cancer Society; European Society of Surgical Oncology; European Oncology Nursing Society; Canadian Cancer Society; European Society for Therapeutic Radiology and Oncology; American Society of Clinical Oncology; European Society of Gynecological Oncology; European Society of Surgical Oncology

Track 5: Rare Ophthalmological Diseases

Ophthalmological Diseases in which Rare, inherited vision disorder in which an individual has frequent or no ability to see color. People with achromatopsia also generally experience some vision loss, especially in brightest light, to which they are extremely cause vision impairment. The severity of the disease achromatopsia varies different. Although there will be no cure or treatment for this disorder type, people with rare Ophthalmological conditions can manage its symptoms. The main thing they get involved as they can wear sunglasses or tinted contact lenses to cope with bright light. They can use magnifiers and other devices for low power vision to help them read, and telescopes to help them see distant objects. Since ophthalmologists perform operation to eyes, and also involving with both surgical and medical specialists to treat the rare conditions in eyes. A multitude of diseases and conditions can be diagnosed with rare eye problems affecting all over

Related Conferences

4th International Conference on Sexually Transmitted Diseases, Jun 19-20, 2017 UK ;International Conference on Vector Borne Diseases ,June 29-30, 2017 Philadelphia, USA;3rd International Conference on Retroviruses and Novel Drugs ,July 27-28, 2017 Vancouver, Canada;3rd International Conference on Influenza ,Aug 21-22 2017 Birmingham, UK;3rd World Congress on Infectious Diseases ,Aug 21-23, 2017 California, San Francisco, USA; 24th Conference on retroviruses and opportunistic infections Feb 13-16, 2017 USA; Keystone Symposia-Malaria: From innovation to eradication, Feb 19-23, 2017 Uganda; Australasian society for infectious diseases annual scientific meeting, Mar 29-Apr 01, 2017; ICHA 2017: 19th International Conference on HIV and AIDS ,May 25-26, 2017 London, UK; STI & HIV World Congress ,July 9-12, 2017 Rio de Janeiro, Brazil

Related Societies:

American Academy of Ophthalmology; American Association for Paediatric Ophthalmology;  Association for Research in Vision and Ophthalmology; European Society of Retina Specialists; Asia Pacific Glaucoma Society; European Society of Cataract & Refractive Surgeons; Ireland Society of Cataract and Refractive Surgeons; Asia Pacific Academy of Ophthalmology; Canadian Society of Refractive Surgery; Japanese Society of Cataract and Refractive Surgery; National Society for the Prevention of Blindness; Vitreo Retina Society of IndiaGlaucoma Society of India;

Track 6: Rare Metabolic Diseases

The phrase metabolism related to all biochemical process and pathways in the human body. Catalysts assume a key part in a large number of these procedures and changes in their capacity, subsequently, of hereditary transformation can prompt issues in these pathways. Metabolic changes can give incredible assorted qualities of signs and manifestations like episodic illness-anorexia, vomiting, and gastric metabolic disorder, lethargy, cardiomyopathy, muscular, gastrointestinal. Drug treatment is utilized to treat metabolic rare conditions; however this represents an oversees challenge to community and hospital pharmacists as they are not accessible in an appropriate formulation for administration.

Related Conferences

3rd International Conference on Retroviruses and Novel Drugs ,July 27-28, 2017 Vancouver, Canada;3rd International Conference on Influenza ,Aug 21-22 2017 Birmingham, UK;3rd World Congress on Infectious Diseases ,Aug 21-23, 2017 California, San Francisco, USA; 4th International Conference on Sexually Transmitted Diseases, Jun 19-20, 2017 UK ;International Conference on Vector Borne Diseases ,June 29-30, 2017 Philadelphia, USA; 24th Conference on retroviruses and opportunistic infections Feb 13-16, 2017 USA; Keystone Symposia-Malaria: From innovation to eradication, Feb 19-23, 2017 Uganda; Australasian society for infectious diseases annual scientific meeting, Mar 29-Apr 01, 2017; ICHA 2017: 19th International Conference on HIV and AIDS ,May 25-26, 2017 London, UK; STI & HIV World Congress ,July 9-12, 2017 Rio de Janeiro, Brazil

Related Societies:

Endocrine Society; American Association of Clinical Endocrinologists; The American Association of Endocrine Surgeons; Association of Program Directors in Endocrinology, Diabetes and Metabolism; Society for Endocrinology; Brazilian Society of  Surgical Endocrinology; British Society for Paediatric Endocrinology and Diabetes; European Society of Endocrinology; International Society of Endocrinology; Pediatric Endocrine Society; FAND - Italian Association of Diabetics; Italian Association for the Defence of the Interests of Diabetics; Italian Society of Diabetology; Australian Diabetes Society

Track 7: Genetic Diseases and Disorders

Genetic disorders may occur due to hereditary, passed down from the parents' genes. In other genetic disorders, defects may be caused by new mutations or changes to the DNA structure. In such cases, the defect will only be passed down if it occurs in the genetic line. The twin disease, such as some forms of cancer, may be caused by an inherited genetic condition in some people, by new mutations changes in other people, and mainly by environmental causes in other people. A genetic disorder is a genetic problem caused by one or more rare abnormalities in the genome, especially a condition that is present from birth conditions (congenital). Most genetic disorders are often rare and affect one person in every several thousands or millions. A single-genedisorder is involving a single mutated genetic condition. Over 4000 human diseases are caused by single-gene faults. Single-gene disorders or syndromes can be passed on to subsequent generations in several ways. Genomic imprinting develops anduniparental disomic, however that may affect inheritance patterns. The rare divisions between recessive and dominant types are not quite even "hard and fast", although the divisions between autosomal associated with X-linked types are involving since the latter types are distinguished purely based on the chromosomal location of the gene.

Related Conferences

4th World Congress on Infection Prevention and Control, Nov 28-29, 2016 (9 Keynotes, 1 Special session, 2 Days,1 Event) Valencia, Spain; International congress on Infectious Diseases, May 11-12, 2017 Barcelona, Spain;5th International Congress on Bacteriology and Infectious Diseases, May 25-26, 2017 USA;4th International Conference on Chronic Obstructive Pulmonary Disease (COPD), May 29-31, 2017 Japan; Annual Conference on Rare Diseases and Orphan Drugs, Oct 26-27, 2016 USA; 2nd International Conference on Flu, Oct 31- Nov 2, 2016 in San Francisco, USA; International Conferences on Rare Diseases and Orphan Drugs Cape 19-22 Oct 2016, South Africa;19th International Conference on Infectious Diseases , Jan 26 - 27, 2017 Sydney Australia; Advances in Basic and Translational Research in Tropical Infectious Diseases ,Mar 12-17, 2017 Hotel Galvez Galveston, TX; Keystone Symposia: New developments in our basic understanding of tuberculosis, Jan 14-18, 2017 Canada; 35th UC Davis Annual infectious diseases conference Feb 03-04, 2017 USA

Related Societies:

American Society of Human Genetics; European Society of Human Genetics; Japan Society of Human Genetics; Genetic Society in China; Indian Society of Genetics; International Genetic Epidemiology Society; FAND - Italian Association of Diabetics; Italian Association for the Defence of the Interests of Diabetics; Rare Diseases UK, Rare Diseases South Africa, Students 4 Rare Diseases

Track 8: Neurological Disorders

Neurodevelopmental diseases conditions sare disabilities related essentially with the working of the neurological framework and cerebrum. While the symptoms and the behaviours of neurological disabilities change or develop contingent upon the array of rare disease, some disabilities are cannot be cured. Analysis and treatment of these disorders can be difficult; treatment may include a mix of professional therapeutic treatment, pharmaceuticals, and disease specific therapies.

Related Conferences

Annual Conference on Rare Diseases and Orphan Drugs, Oct 26-27, 2016 USA; 2nd International Conference on Flu, Oct 31- Nov 2, 2016 in San Francisco, USA;4th World Congress on Infection Prevention and Control, Nov 28-29, 2016 (9 Keynotes, 1 Special session, 2 Days,1 Event) Valencia, Spain; International congress on Infectious Diseases, May 11-12, 2017 Barcelona, Spain;5th International Congress on Bacteriology and Infectious Diseases, May 25-26, 2017 USA;4th International Conference on Chronic Obstructive Pulmonary Disease (COPD), May 29-31, 2017 Japan; International Conferences on Rare Diseases and Orphan Drugs Cape 19-22 Oct 2016, South Africa;19th International Conference on Infectious Diseases , Jan 26 - 27, 2017 Sydney Australia; Advances in Basic and Translational Research in Tropical Infectious Diseases ,Mar 12-17, 2017 Hotel Galvez Galveston, TX; Keystone Symposia: New developments in our basic understanding of tuberculosis, Jan 14-18, 2017 Canada; 35th UC Davis Annual infectious diseases conference Feb 03-04, 2017 USA

Related Societies:

American Neurological Association; Neurological Society of India; Pennsylvania Neurological Society;   Albanian Society of Neurology; Armenian Scientific-Practical Union of Neurologists; Austrian Society of Neurology; Spanish Society of Neurology; Swedish Neurological Society; Netherlands Society of Neurology;  German Society of Neurology; Hellenic Neurological Society

Track 9: Rare Pulmonary Diseases

The condition of rare lung disorders varies widely by disease type. Uncommon lung diseases affect at least 1 in every 200 persons. The lungs may also be getting involved as a rare manifestation of another more common disorder, namely Marfan syndrome. Some lung diseases are occurs in rare that they only have been described in case reports. The causes with pathophysiology of these diseases are varied in number and complex. Many have a genetic basis, and most diseases have genetic influence. The diseases and microorganisms may play a significant role, especially in those diseases in which the patient’s immune defense has been developed.

The Rare conditions in lung infections influence no less than 1 in each 200 people affecting with pulmonary rare diseases. The functioning of uncommon lung disorders fluctuating broadly by sickness sort. The lungs may likewise be included as a rare lung manifestation of another more basic disease condition. Some lung ailments are rare to the point that they just have been discussed in the event that reports. The causes and pathophysiology of these infections are different and complex. Numerous conditions have a hereditary basis, and most infections have genetic impact. The environment and micro bacterial diseases involving with the lungs may play a role, particularly in with those illnesses in which the patient's resistant barrier has been compromised.

Related Conferences

3rd International Conference on Retroviruses and Novel Drugs ,July 27-28, 2017 Vancouver, Canada;3rd International Conference on Influenza ,Aug 21-22 2017 Birmingham, UK;3rd World Congress on Infectious Diseases ,Aug 21-23, 2017 California, San Francisco, USA; 4th International Conference on Sexually Transmitted Diseases, Jun 19-20, 2017 UK ;International Conference on Vector Borne Diseases ,June 29-30, 2017 Philadelphia, USA; 24th Conference on retroviruses and opportunistic infections Feb 13-16, 2017 USA; Keystone Symposia-Malaria: From innovation to eradication, Feb 19-23, 2017 Uganda; Australasian society for infectious diseases annual scientific meeting, Mar 29-Apr 01, 2017; ICHA 2017: 19th International Conference on HIV and AIDS ,May 25-26, 2017 London, UK; STI & HIV World Congress ,July 9-12, 2017 Rio de Janeiro, Brazil

Related Societies:

Japanese Respiratory Society; Portuguese Society of Pulmonology; Peruvian Chest Society; Russian Respiratory Society; The Australian Lung Foundation; Portuguese Respiratory Society; COPD Foundation; Asian Pacific Society of Respirology; Portuguese Respiratory Society; South African Thoracic Society

Track 10: Haematological Diseases

There are many conditions affecting the human hematological system — the biological system that includes plasma, platelets, leukocytes, and erythrocytes, which the major component portions of blood and the bone marrow.  It also implies structural abnormalities in the globin proteins in rare hematlogical analysis. It also usually occurs in underproduction of normal globin proteins, often leads through mutations in regulatory genes. The two conditions may overlap, however, since some conditions which further causes of rare abnormalities in globin haematological proteins (hemoglobinopathy) also influence the production (thalassemia).Hemoglobin variants are a part of the normal embryonic and fetal development, but may also be pathologic mutant forms of hemoglobin, caused by variations in genetics diseases in rare conditions. Other variants cause no detectable pathology, and are thus considered non-pathological variants. In patients predisposed for rapid clearance of red blood cells, this may lead to early destroy of cells infected with the parasite and increasing the chance of survivasl for the carrier of the trait.

Related Conferences

4th International Conference on Sexually Transmitted Diseases, Jun 19-20, 2017 UK ;International Conference on Vector Borne Diseases ,June 29-30, 2017 Philadelphia, USA;3rd International Conference on Retroviruses and Novel Drugs ,July 27-28, 2017 Vancouver, Canada;3rd International Conference on Influenza ,Aug 21-22 2017 Birmingham, UK;3rd World Congress on Infectious Diseases ,Aug 21-23, 2017 California, San Francisco, USA; 24th Conference on retroviruses and opportunistic infections Feb 13-16, 2017 USA; Keystone Symposia-Malaria: From innovation to eradication, Feb 19-23, 2017 Uganda; Australasian society for infectious diseases annual scientific meeting, Mar 29-Apr 01, 2017; ICHA 2017: 19th International Conference on HIV and AIDS ,May 25-26, 2017 London, UK; STI & HIV World Congress ,July 9-12, 2017 Rio de Janeiro, Brazil

Related Societies:

International society of Hematology; American Society of Hematology; European society of Hematology; British Society of Hematology; European society of Pediatric Hematology Oncology; Emirates society of Hematology; International Society for Laboratory Hematology; Haematology Society of Australia and New Zealand; The Canadian Hematology Society; American Society of Clinical Oncology; Michigan society of Hematology; Malaysian society of Hematology

Track 11: Nursing and Rare Disease

Rare diseases are often considered as difficult because of the rare conditions occurs. It’s impossible to prepare for every possible diagnosis, so many nurses further more learning about more common ailments in school and are expected to learn about rare diseases on the job. At times the patient might be the best source of information for the rare conditions to diagnose. Nurses already know that listening to the patient is an invaluable tool to the patients, but in the case of rare disease would be one of the only options available at the onset of care. Rare disease management helping out further for some nurses, however. There have been instances when a rare disease becomes more frequently examined and diagnosed, but nurses are in a unique wide position to advance the knowledge and awareness about rare disease due to their exposure and involvement in medicine.      

Related Conferences

4th World Congress on Infection Prevention and Control, Nov 28-29, 2016 (9 Keynotes, 1 Special session, 2 Days,1 Event) Valencia, Spain; International congress on Infectious Diseases, May 11-12, 2017 Barcelona, Spain;5th International Congress on Bacteriology and Infectious Diseases, May 25-26, 2017 USA;4th International Conference on Chronic Obstructive Pulmonary Disease (COPD), May 29-31, 2017 Japan; Annual Conference on Rare Diseases and Orphan Drugs, Oct 26-27, 2016 USA; 2nd International Conference on Flu, Oct 31- Nov 2, 2016 in San Francisco, USA; International Conferences on Rare Diseases and Orphan Drugs Cape 19-22 Oct 2016, South Africa;19th International Conference on Infectious Diseases , Jan 26 - 27, 2017 Sydney Australia; Advances in Basic and Translational Research in Tropical Infectious Diseases ,Mar 12-17, 2017 Hotel Galvez Galveston, TX; Keystone Symposia: New developments in our basic understanding of tuberculosis, Jan 14-18, 2017 Canada; 35th UC Davis Annual infectious diseases conference Feb 03-04, 2017 USA

Related Societies:

Academy of Medical-Surgical Nurses; Academy of Neonatal Nursing; Air & Surface Transport Nurses Association; Alliance for Psychosocial Nursing; American Academy of Ambulatory Care Nursing; American Association of Moderate Sedation Nurses; American Association of Nurse Life Care Planners; Canadian Society for Mucopolysaccharide and Related Diseases; Rare Diseases UK, Rare Diseases South Africa, Students 4 Rare Diseases, National Organization for Rare Disorders; American Association of Pharmaceutical Scientists

Track 12: Therapies for rare diseases

Critical insights in the advancement of gene and cell therapeutic disorders have opened up the likelihood of durably treating and potentially curing a number of uncommon rare genetic diseases. The present therapeutic methodologies include gene and cell therapy: In gene therapy, a conveyance vehicle (as an engineered virus) will convey a right form of the gene of interest or will mute the diseased gene in a patient’s cells. In cell therapy, an engineered cell line is utilized to present appropriately genetic conditions in order to reflect the intended therapeutic impact. There are targeted therapies developed to treat cancer at the malignant cellular level by affecting the biologic pathways particular to cancerous cells. It was the consequence of many years of research seeking to implement the biological mechanisms of the disease.

Related Conferences

5th International Congress on Bacteriology and Infectious Diseases, May 25-26, 2017 USA;4th International Conference on Chronic Obstructive Pulmonary Disease (COPD), May 29-31, 2017 Japan; Annual Conference on Rare Diseases and Orphan Drugs, Oct 26-27, 2016 USA;2nd International Conference on Flu, Oct 31- Nov 2, 2016 in San Francisco, USA;4th World Congress on Infection Prevention and Control, Nov 28-29, 2016 (9 Keynotes, 1 Special session, 2 Days,1 Event) Valencia, Spain; International congress on Infectious Diseases, May 11-12, 2017 Barcelona, Spain; International Conferences on Rare Diseases and Orphan Drugs Cape 19-22 Oct 2016, South Africa;19th International Conference on Infectious Diseases , Jan 26 - 27, 2017 Sydney Australia; Advances in Basic and Translational Research in Tropical Infectious Diseases ,Mar 12-17, 2017 Hotel Galvez Galveston, TX; Keystone Symposia: New developments in our basic understanding of tuberculosis, Jan 14-18, 2017 Canada; 35th UC Davis Annual infectious diseases conference Feb 03-04, 2017 USA

Related Societies:

American Society of Clinical Oncology; American Cancer Society; European society of Pediatric Hematology Oncology; Indian Cancer Society; European Society of Surgical Oncology; European Oncology Nursing Society; Canadian Cancer Society; European Society for Therapeutic Radiology and Oncology; American Society of Clinical Oncology; European Society of Gynecological Oncology; European Society of Surgical Oncology

Track 13: Potency of Orphan drugs

Orphan drugs are considered to be medicinal products intended for the diagnosis, prevention or the treatment of rare diseases. Approval of all drugs in rare diseases conditions must be based on effectivenessof substantial evidence of effectiveness in treating or preventing the condition with the evidence of safety for the treatment use. Over the last decade of 30 years, more than 400 medicines representing 447 separate medicinal indications have been approved to treat conditions and diseases symptoms rare diseases, compared to lesser than 10 in the 1970s.

Related Conferences

3rd International Conference on Retroviruses and Novel Drugs ,July 27-28, 2017 Vancouver, Canada;3rd International Conference on Influenza ,Aug 21-22 2017 Birmingham, UK;3rd World Congress on Infectious Diseases ,Aug 21-23, 2017 California, San Francisco, USA; 4th International Conference on Sexually Transmitted Diseases, Jun 19-20, 2017 UK ;International Conference on Vector Borne Diseases ,June 29-30, 2017 Philadelphia, USA; 24th Conference on retroviruses and opportunistic infections Feb 13-16, 2017 USA; Keystone Symposia-Malaria: From innovation to eradication, Feb 19-23, 2017 Uganda; Australasian society for infectious diseases annual scientific meeting, Mar 29-Apr 01, 2017; ICHA 2017: 19th International Conference on HIV and AIDS ,May 25-26, 2017 London, UK; STI & HIV World Congress ,July 9-12, 2017 Rio de Janeiro, Brazil

Related Societies:

American Association of Pharmaceutical Scientists; American College of Clinical Pharmacy;  American Institute of the History of Pharmacy; Georgia Pharmacy Association; American Association of Clinical Endocrinologists; The American Association of Endocrine Surgeons; Association of Program Directors in Endocrinology, Diabetes and Metabolism; Society for Endocrinology; Brazilian Society of  Surgical Endocrinology; British Society for Paediatric Endocrinology and Diabetes;

Track 14: Strategies for Diagnosis &Treatment

Diagnosis and the treatment of a rare disease become complicated because of the fact that many health care providers may have restricted involvement with the identification of the particular disease condition with the diagnosis of rare diseases. Additionally, analysis before manifestation onset or diagnosis early stage in the disease can be challenging. Biopharmaceutical specialists in the field have utilized new advances and the developing exploratory comprehension of multiple rare diseases to develop and diagnose ground breaking therapies over the last 10 years. In the last decade, more than 230 new orphan medical drugs were approved by the U.S. Food and Drug Administration (FDA). In 2015 alone, about half (47%) of novel latest drug approvals were for rare diseases. Disease specific therapies need to be developed for productive results in treatment of Rare Diseases.

Related Conferences

5th International Congress on Bacteriology and Infectious Diseases, May 25-26, 2017 USA;4th International Conference on Chronic Obstructive Pulmonary Disease (COPD), May 29-31, 2017 Japan; Annual Conference on Rare Diseases and Orphan Drugs, Oct 26-27, 2016 USA;2nd International Conference on Flu, Oct 31- Nov 2, 2016 in San Francisco, USA;4th World Congress on Infection Prevention and Control, Nov 28-29, 2016 (9 Keynotes, 1 Special session, 2 Days,1 Event) Valencia, Spain; International congress on Infectious Diseases, May 11-12, 2017 Barcelona, Spain; International Conferences on Rare Diseases and Orphan Drugs Cape 19-22 Oct 2016, South Africa;19th International Conference on Infectious Diseases , Jan 26 - 27, 2017 Sydney Australia; Advances in Basic and Translational Research in Tropical Infectious Diseases ,Mar 12-17, 2017 Hotel Galvez Galveston, TX; Keystone Symposia: New developments in our basic understanding of tuberculosis, Jan 14-18, 2017 Canada; 35th UC Davis Annual infectious diseases conference Feb 03-04, 2017 USA

Related Societies:

American Pediatric Society; Society for Pediatric Research; The Latin American Society for Pediatric Research; Pediatric Academic Societies; Rare Diseases UK, Rare Diseases South Africa, Students 4 Rare Diseases; European Oncology Nursing Society; Canadian Cancer Society; European Society for Therapeutic Radiology and Oncology; American Society of Clinical Oncology; European Society of Gynecological Oncology; European Society of Surgical Oncology

Track 15: Legal issues related to rare diseases

The absence of lawful controls on treating the uncommon rare diseases in numerous nations in the world, because of patients and their families are getting affected with various diseases obstructions when requesting for professional help. The first country to pass and approve the Orphan Drug Act in USA, followed by Japan in 1993, and eventually the European Union in 2000. The absence of a special International Disease Classification about disease leading to the IDC blocks the usage of a framework for the patients who are experiencing these diseases in the world. The main motto is to focus on rare diseases from the aspect of acceptable strategies or unsatisfactory social results is of critical need. 

Related Conferences

4th International Conference on Sexually Transmitted Diseases, Jun 19-20, 2017 UK ;International Conference on Vector Borne Diseases ,June 29-30, 2017 Philadelphia, USA; 3rd International Conference on Influenza ,Aug 21-22 2017 Birmingham, UK; 3rd International Conference on Retroviruses and Novel Drugs ,July 27-28, 2017 Vancouver, Canada; 4th International Conference on Chronic Obstructive Pulmonary Disease (COPD), May 29-31, 2017 Japan; 3rd World Congress on Infectious Diseases ,Aug 21-23, 2017 California, San Francisco, USA; 4th International Conference on Sexually Transmitted Diseases, Jun 19-20, 2017 UK ;International Conference on Vector Borne Diseases ,June 29-30, 2017 Philadelphia, USA; Australasian society for infectious diseases annual scientific meeting, Mar 29-Apr 01, 2017;  19th International Conference on HIV and AIDS ,May 25-26, 2017 London, UK;STI & HIV World Congress ,July 9-12, 2017 Rio de Janeiro, Brazil; 24th Conference on retroviruses and opportunistic infections Feb 13-16, 2017 USA; Keystone Symposia-Malaria: From innovation to eradication, Feb 19-23, 2017 Uganda;

Related Societies:

Academy of Medical-Surgical Nurses; Academy of Neonatal Nursing; Air & Surface Transport Nurses Association; Alliance for Psychosocial Nursing; American Academy of Ambulatory Care Nursing; American Association of Moderate Sedation Nurses; American Association of Nurse Life Care Planners; Canadian Society for Mucopolysaccharide and Related Diseases; Rare Diseases UK, Rare Diseases South Africa, Students 4 Rare Diseases, National Organization for Rare Disorders; American Association of Pharmaceutical Scientists

Track 16: Current research on rare diseases

Resources needed to be conduct research experiments like databases, biological approach research centres, registries, diagnostic testing and associated with national and international epidemiological and pharma related field systems need to be improved at faster rate and should be emphasised. There are now involving 4,770 progressing research projects, barring clinical trials, covering numerous diseases and research on this area requires a multidisciplinary approach in order to discover creative therapies for the early diagnosis and treatment methods.  Not very many studies have been tending to the requirements of the pediatric population with rare diseases independently organizing from that of grown-ups. However, since about 50 to 75% of the rare diseases begin in childhood, these pediatric disorders deserve special priority.

Related Conferences

3rd International Conference on Retroviruses and Novel Drugs ,July 27-28, 2017 Vancouver, Canada;3rd International Conference on Influenza ,Aug 21-22 2017 Birmingham, UK;3rd World Congress on Infectious Diseases ,Aug 21-23, 2017 California, San Francisco, USA; 4th International Conference on Sexually Transmitted Diseases, Jun 19-20, 2017 UK ;International Conference on Vector Borne Diseases ,June 29-30, 2017 Philadelphia, USA; 24th Conference on retroviruses and opportunistic infections Feb 13-16, 2017 USA; Keystone Symposia-Malaria: From innovation to eradication, Feb 19-23, 2017 Uganda; Australasian society for infectious diseases annual scientific meeting, Mar 29-Apr 01, 2017; ICHA 2017: 19th International Conference on HIV and AIDS ,May 25-26, 2017 London, UK; STI & HIV World Congress ,July 9-12, 2017 Rio de Janeiro, Brazil

Related Societies:

Rare Diseases UK, Rare Diseases South Africa, Students 4 Rare Diseases, National Organization for Rare Disorders; American Association of Pharmaceutical Scientists; Rare Diseases South Africa, Students 4 Rare Diseases, National Organization for Rare Disorders; Rare Diseases Europe; Rare Disorders Society; BPSU – Rare

Market Analysis

Importance & scope:

Rare diseases are rare and often debilitating or even life-threatening diseases or conditions with a prevalence of 0.65%-1%, the cause of rare diseases is mostly genetic in nature and sometimes it may be as a result of infections or degenerative causes.

 80% of rare diseases have identified genetic origins, 50% of rare diseases affect children, and 30% of patients with rare diseases die before the age of 5. A rare disease is defined as one that affects less than 5 in 10,000 of the general population in European Union and fewer than 200,000 people in the United States. Worldwide it is estimated that 350 million people suffer from rare diseases. The above data urges a need for enhanced efforts in the fields of fundamental, translational, epidemiological, health services research and the current focus of Research studies is on Orphan drugs for safe and effective treatment. This 2nd World Congress Rare Diseases and Orphan Drugs would help researchers, academicians and young research fellows from across the globe to address the problem and unlock the understanding on rare diseases and its emerging technologies.

Why London?

Rare diseases are a complex group of heterogeneous maladies and are known for their irregularity. Just around 25% of uncommon diseases identified have their molecular basis characterized. There a numerous difficulties extending from illness acknowledgment to conclusion and advancement of new medications .UK has one of the biggest bio groups which work in association in this area of research,. London, the capital city of England is situated on River Thames nearby the island of Great Britain and is a popular tourist destination. London is a leading global city in areas of arts, commerce, education, entertainment, finance, healthcare, research facilities, tourist destination, and best transportation. London denote a one of a kind spot in rare diseases scientific research which includes top universities, research centres etc., these centres will provide research specialists the support and facilities they need to produce results. It also includes infrastructure that supports the research, and aims to consolidate its role as one of the world's driving places for the treatment of children with rare diseases. London and the neighbouring states are continuously endeavouring to create awareness and improve the health of individuals suffering from rare diseases. The EU has started a consortium in 2011 named “The International Rare Diseases Research Consortium” with an objective to develop new therapies and find novel methods to diagnose the disease. The UK has one of the strongest and most productive life sciences sectors in the world and London is a location of choice for pioneering, collaborative research of this nature. 2nd World Congress on Rare Diseases and Orphan Drugs to be held at London would benefit participants from all around the globe and drive forward research in this area.

Major Universities associated with Rare Diseases research

Australian National University, Australia

Benha University, Egypt

Center for Clinical Pharmacology, Belgium

Center for Rare Neurological Diseases, USA

Charles Darwin University Casoria Australia

Columbia University Medical Center, United States

Columbia University, USA

Curtin University Bentley, Australia

Dar Al Uloom University, Saudi Arabia

Duke University, USA

Emory University, USA

GMEC, The Global Medical Excellence Cluster

Guangzhou Medical University, China

Harvard University, United States

Harvard University, USA

Imperial College London, United Kingdom

Iqbal Chest Centre, Bangladesh

John Hopkins University, USA

Johns Hopkins University, United States

Karolinska University, Sweden

Kindai University, Japan

King Saud Bin Abdulaziz University, Saudi Arabia

King's College London, UK

Kumamoto University, Japan

Linnaeus University, Sweden

Macquarie University, Australia

Mayo Clinic College of Medicine, USA

McGill university   Montréal, Canada

McMaster University, Canada

Medi7 Bentleigh, Australia

Murdoch University   Murdoch, Australia

Newcastle University, Australia

Northwestern University, Qatar

Osaka University, Japan

Oxford University, UK

Philip Morris International R&D, Switzerland

Pompeu Fabra University, Spain

Queen Mary University, UK

Rare Genomics Institute, USA

Research Institute of Hospital del Mar, Spain

Samsung Medical Center, South Korea

St George’s University of London, UK

St. George Hospital, Australia

Stanford University, USA

Tasmanian Health Service, Australia

The Chest & Heart Association of Bangladesh, Bangladesh

The Fourth Hospital of Harbin Medical University, China

The Jikei University School of Medicine, Japan

Tufts university, United States

United Hospital, Bangladesh

University College London, UK

University Of British Columbia, Canada

University Of Buffalo, United States

University Of California Los Angeles, United States

University of California, USA

University of Cambridge, USA

University of Canberra Bruce, Australia

University of Celiac Disease Center, USA

University Of Chicago Medicine, USA

University Of Colorado, USA

University Of Groningen, Netherlands

University Of London Imperial College Of Science Technology And Medicine, UK

University of Maastricht, Netherlands

University Of Maryland Medical  Center, United States

University Of Maryland Medical Center, Australia

University Of Melbourne, Australia

University Of Minnesota, United States

University of Newcastle, Australia

University of Pennsylvania, USA

University of Pittsburgh Study

University Of Pittsburgh, USA

University of Queensland, Australia

University of Tasmania, Australia

University Of Toronto, Canada

University of Valencia, Spain

University of Washington, USA

University Of Washington, USA

University of Zurich, Switzerland

University-of-the-sunshine-coast, Australia

Weill Cornell Medical College, Qatar

Yale University School of Medicine, USA

Yonsei University, South Korea

                

 

Major Research Associations related to Rare Diseases and Orphan Drugs

Alzheimer's Disease Organizations

Ann & Robert H. Lurie Children’s Hospital

Birmingham children’s Hospital

Boston Children’s Hospital

Canadian Organization for Rare Diseases

Chicago Rare Disease Foundation

Children’s hospital of Pittsburgh

Comer Children’s Hospital – University of Chicago

Cystic Fibrosis Foundation

European Union Committee of Experts on Rare Diseases

EURORDIS Rare Diseases Europe

EveryLife Foundation for Rare Diseases

Global Genes Allies in Rare Diseases

Guardian Hands Foundation

Hospitals Associated with Rare Diseases Research

IRDR Intractable & Rare Diseases Research

Japan Patient Association

Multiple Myeloma Research Foundation

National Alliances for Rare Diseases

National Institute of Health (NIH)

National Organization for Rare Diseases

Organization for Rare Diseases India (ORDI)

Orphan Europe

 Philippine Society for Orphan Disorders

Rare Disease UK

Rare Diseases or Syndromes and Clinical Societies

Rare Diseases Patient Association Funding

Rare Diseases South Africa

 Rare Diseases Translational Research Collaboration

Rare Disorders Society Singapore

RARE Foundation Alliance

Royal Society of Medicine

Short Bowel Syndrome Foundation

Students4RareDiseases

 The Asia-Pacific Alliance of Rare Disease Organisations

The Boler-Parseghian Center for Rare & Neglected Diseases

The Boler-Parseghian Center for Rare & Neglected Diseases

The Children’s Hospital of Philadelphia

The Every Life Foundation for Rare Diseases

The Genetic and Rare Disorders Organization

The Greek Alliance for Rare Diseases

The Manton Center for Orphan Disease Research

U.S. Food and Drug Administration

UCLA Health

US hospital for Rare Disease Research

                     

 

Major Companies Associated with Rare Diseases Research

Abbott Laboratories, UK

Actavis, USA

Aegerion Pharmaceuticals, Japan

Almirall, Spain

Amgen, USA

Amicus Therapeutics, USA

Amphastar Pharmaceuticals, Inc

Araim Pharmaceuticals

Astellas Pharma US

AstraZeneca, Switzerland

AstraZeneca, UK

Baxter International Deerfield

Bayer HealthCare, Germany

Bayer, Germany

Beacon Pharmaceuticals, Bangladesh

Biotie Therapies Corp, Finland

Bioxyne Limited, Australia

Boehringer Ingelheim, Germany

Centrapharm Ltd, UK

Chiesi Pharmaceutical, Italy

Cohero Health, USA

Daiichi Sankyo, Japan

Dohmen Life Science

European Medicines Agency

Forest Laboratories, USA

Gecko Health, USA

Generics (UK) Ltd, UK

Genus Oncology Vernon Hills, USA

Genzyme, USA

Gilead sciences, USA

GlaxoSmithKline, UK

Glaxosmithkline, UK

Gsk, London

Kissei Pharmaceutical Co., Ltd, Japan

Lallemand Pharma, Switzerland

Marathon Pharmaceuticals

Merck & Co, USA

Millennium Pharmaceuticals

Napp Pharmaceuticals Ltd, UK

Novartis, Switzerland

NPS Pharmaceuticals

Octapharma, USA

Onyx Pharmaceuticals, USA

Otsuka Holdings Co., Ltd, Japan

Panmira Pharmaceuticals, LLC, USA

Pearl Therapeutics, Inc

Pfizer, USA

PharmaMar, USA

Prosensa, Netherlands

PT Boehringer Ingelheim, Indonesia

Queensland Respiratory Laboratory Pty. Ltd, Australia

Ranbaxy Laboratories Limited

Raptor Therapeutics

Roche, Switzerland

Sanofi, France

Sarepta Therapeutics, USA

Sigma-Tau Pharmaceuticals, Italy

Sunovion Pharmaceuticals, USA

Swedish Orphan Biovitrum AB, Sweden

Takeda, Japan

Vertex Pharmaceuticals, USA

ViroPharma

ViroPharma

ViroPharma, USA

Visionary Pharmaceuticals, Inc, USA

Yungjin Pharm Ind. Co., Ltd, South Korea

                              

 

Market Research

There are more than 6,000 perceived uncommon diseases and it has been assessed that a further 5 are depicted every week.75% of rare diseases influence children.30% of rare disease patients die before 5 years old and,whilst each affects less than 0.1% of the population, the quantity of patients influenced by rare diseases is around 27-36 million in the EU, 25-30 million in the US, and 350 million people are affected around the world, but the true burden of rare diseases is difficult to estimate hard to evaluate subsequent to epidemiological information for most uncommon infections are not accessible. Among the rare diseases recognized and contemplated by EURORIDS it is found that 28.1% autosomal recessive inheritance,26.5% autosomal dominant inheritance, some are sporadic and few are with no etiology.There will be a steady increase in the cumulative number of diseases for which an orphan drug is approved, averaging just over 5 new diseases per year over the next 10 years. The annual per patient cost of global orphan drugs was varies between €1,251 and €407,631, with the median cost being €32,242 per year. The share of the total pharmaceutical market represented by orphan drugs is anticipated to increase from 3.3% in 2010 to a range of 4.6% in 2016 after which it is expected to level off through 2020. The global sales for orphan drugs are estimated at $178 billion, growing by11.7% per year, over the five year period between 2015 and 2020, nearly double the yearly growth of the overall prescription drug market, There are more than 6000 rare diseases are occurring. On the whole, rare diseases may affect 30 million European Union citizens, affects less than 1 in 2000.

Life expectancy 

Among the couple of rare diseases studied it is found that 37.5% had ordinary lifespan - 25.7% possibly deadly during childbirth or before 5 years old - 36.8% lessened lifespan, depending on the seriousness, penetrance or type (child, juvenile or adult types) of the disease.

 

                               

   

                         

 

Funds for research

EU has declared 38 million euro financing for exploration towards orphan medicines and for the improvement of a central worldwide rare disease hub involving 70 institutions. The EU subsidizing encouraged the arrangement of multidisciplinary groups from colleges, research associations, SMEs, industry and patient associations from crosswise over Europe and beyond. National Institute for Health Research had released funds of £5 million for each annum for the Rare Diseases Translational Research Collaboration furthermore NIH funded 19 proceeding and new clinical examination consortia to fortify the progressing clinical exploration in rare diseases.

 

 

Past Conference Report

Rare Diseases 2016

 

Rare Diseases-2016: Past Conference Report

With the overwhelming success of the previous conference, Conference Series LLC hosted Annual Congress on Rare Diseases and Orphan Drugs during October 26-27, 2016 at Chicago, USA (Rare Diseases-2016). The conference was marked with the attendance of Editorial Board Members of supported Conference Series LLC journals, scientists, young and brilliant researchers, business delegates and talented student communities representing more than 20 countries, who made this conference fruitful and productive. This conference was based on the theme, “The voice of rare diseases - research and treatment” which included the following scientific tracks:

· Different Types of Rare Diseases

· Clinical Research and Public Awareness

· Mystery Diagnosis of Rare Diseases

· Challenges in Rare Diseases Treatment

· Rare Diseases in Cancer

· Rare Diseases in Aging

· Rare Infectious Diseases and Immune Deficiencies

· Clinical Immunology

· Orphan Drugs, Development Trends and Strategies

· Orphan Drugs and Ethical Issues

· Future Hereditary and Rare Diseases e Prospects of Rare Diseases

· Entrepreneurs Investment Meet

 

We are thankful to our below Honorable Guests for their generous support and suggestions:

· Philippe Jouvet, Sainte-Justine Hospital University of Montreal, Canada

· Stephen Shrewsbury, Fortuna Fix, USA

· Thomas C Chen, Keck School of Medicine of USC, USA

 

The conference proceedings were carried out through various scientific-sessions and plenary lectures, of which the following topics were highlighted as Keynote presentations:

· Title: The rare diseases clinical research network (RDCRN) program (a model for collaborative research) and resources at NCATS, NIH

Rashmi Gopal-Srivastava, NCATS, NIH, USA

· Title: Inside track to an orphan designation

Timothy Cote, Cote Orphan, USA

· Title: How patient organizations can change the game in innovation and drug marketing: Example of AFMTelethon

Serge Braun, AFMTelethon, France

 

Conference Sessions Chair and Co-Chair:

· Amrik Sahota, Rutgers University, USA

· Lisa Baumbach-Reardon, Translational Genomics Research Institute, USA

· Alan B Moy, The John Paul II Medical Research Institute and Cellular Engineering Technologies, USA

 

Conference Series LLC has taken the privilege of felicitating Rare Diseases-2016 Organizing Committee, Editorial Board Members and Keynote Speakers who supported for the success of this event. The esteemed guests, keynote speakers, well-known researchers and delegates shared their innovative research and vast experience through their fabulous presentations at the podium of grand Rare Diseases-2016. We are glad to inform that all accepted abstracts for the conference have been published in Conference Series LLC Journal of Genetic Syndromes & Gene Therapy as a special issue.

We are also obliged to various delegate experts, company representatives and other eminent personalities who supported the conference by facilitating active discussion forums. We sincerely thank the Organizing Committee Members for their gracious presence, support and assistance. With the unique feedback from the event, Conference Series LLC would like to announce the commencement of the "2nd World Congress on Rare Diseases and Orphan Drugs" during June 29-30, 2017 in London, UK

                         Let us meet again @ Rare Diseases-2017

   For more information please Visit:                                 http://rarediseases.conferenceseries.com/europe/

 

 


Past Reports  Gallery  

To Collaborate Scientific Professionals around the World

Conference Date June 29-30, 2017

For Sponsors & Exhibitors

Sponsorship Opportunities

Speaker Opportunity

Supported By

Journal of Clinical Infectious Diseases & Practice Journal of Clinical Trials Journal of Neuroinfectious Diseases Journal of Genetic Syndromes & Gene Therapy

All accepted abstracts will be published in respective Conferenceseries International Journals.

Abstracts will be provided with Digital Object Identifier by


Media partners & Collaborators

Media Partner

Collaboration